AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hein, P. A.
Right arrow Articles by Hug, E. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hein, P. A.
Right arrow Articles by Hug, E. B.

Diffusion-Weighted Imaging in the Follow-up of Treated High-Grade Gliomas: Tumor Recurrence versus Radiation Injury

Patrick A. Heina, Clifford J. Eskeyb, Jeffrey F. Dunnb and Eugen B. Huga

a Section of Radiation Oncology, Norris Cotton Cancer Center, Lebanon, NH
b Department of Radiology, Dartmouth-Hitchcock Medical Center, Lebanon, NH



View larger version (113K):

[in a new window]
 
FIG 1. Patient 16 (nonrecurrence group).

A–C, Gadolinium-enhanced T1-weighted (400/14) (A), FLAIR (10,002/175/2200) (B), and DW echo-planar (10000/114.5, b = 1000 s/mm2) (C) representative axial MR images obtained at follow-up after radiation therapy show a small periventricular enhancing lesion in the left frontal lobe, with a surrounding area of T2 prolongation on the FLAIR image consistent with perifocal edema. Postsurgical changes include an area of prior resection of the primary neoplasm (anaplastic astrocytoma) in the left frontal lobe. Enhancement resolved after hyperbaric oxygen therapy.

D, ADC map from the DW image (b = 0, 1000 S/mm2). This patient from the nonrecurrence group exhibited a mean ADC in the enhancing lesion of 1.33 x 10-3 mm/s2, a mean ADC in T2 prolongation of 0.91 x 10-3 mm/s2, and a normalized ADC ratio of the enhancing region of 1.87. X indicates ROI of the enhancing lesion; Y, ROI in T2 prolongation.



View larger version (133K):

[in a new window]
 
FIG 2. Representative follow-up axial MR images after combined therapy for glioblastoma multiforme in patient 8 (recurrence group).

A–C, Gadolinium-enhanced T1-weighted MR image (400/14) (A), FLAIR MR image (10,002/175/22000) (B), and ADC map from DW image (b = 0, 1000 s/mm2) (C) obtained at 7-month follow-up after radiation treatment show a left parietotemporal mass with surrounding T2 prolongation.

D–F, Gadolinium-enhanced T1-weighted MR image (400/14) (D), FLAIR MR image (10,002/175/22000 (E), and ADC map from DW image (b = 0, 1000 s/mm2) (F) show a new focus of enhancement in the left basal ganglia at 7-month follow-up after radiation treatment. Further follow-up imaging (not shown) revealed marked progression of enhancement and T2 prolongation. Patient had progressive functional deterioration in clinical course. This patient from the recurrence group exhibited a mean ADC in the enhancing lesion of 1.13 x 10-3 mm/s2, a mean ADC in T2 prolongation of 1.64 x 10-3 mm/s2, and a normalized ADC ratio of the enhancing region of 1.35. X indicates ROI of the enhancing lesion. ROI in T2 prolongation was drawn in a different section.



View larger version (68K):

[in a new window]
 
FIG 3. Patient 12 (recurrence group).

A and B, Gadolinium-enhanced T1-weighted (400/14) (A) and FLAIR (10,002/175/2200) (B) representative axial MR images obtained at follow-up show a focus of enhancement close to the resection site (resection of an anaplastic astrocytoma) in the right frontal lobe, with surrounding T2 prolongation. Marked progression of enhancement and perifocal edema were noted on further follow-up images (not shown). Patient had progressive functional deterioration in clinical course, and chemotherapy was restarted.

C, ADC map from DW image (b = 0, 1000 s/mm2). This patient from the recurrence group exhibited a mean ADC in the enhancing lesion of 1.26 x 10-3 mm/s2, a mean ADC in T2 prolongation of 1.51 x 10-3 mm/s2, and a normalized ADC ratio of the enhancing region of 1.62. X indicates ROI of the enhancing lesion; Y, ROI in T2 prolongation.



View larger version (8K):

[in a new window]
 
FIG 4. Box and whisker plot compares mean ADC values between the recurrence (REC) and nonrecurrence (NON-REC) groups. Brackets indicate the range of data; boxes represent the distance between the first and third quartiles, with the median between them marked with a diamond.



View larger version (8K):

[in a new window]
 
FIG 5. Box and whisker plot compares ADC ratios between the recurrence (REC) and nonrecurrence (NON-REC) groups. Brackets indicate the range of data; boxes represent the distance between the first and third quartiles, with the median between them marked with a diamond.



View larger version (90K):

[in a new window]
 
FIG 6. A, Recurrent neoplasm in patient 6. Photomicrograph (hematoxylin-eosin stain; original magnification, X120) shows the lesion was a pleomorphic, hypercellular astrocytic neoplasm (arrow) with areas of tumor necrosis and prominent endothelial proliferation.

B, Histology of treatment effects in patient 13. Photomicrograph (Hematoxylin-eosin stain; original magnification, X120) of biopsy specimen in this patient from the nonrecurrence group shows reactive gliosis and radiation changes, with necrosis of nonneoplastic brain.